Solutions for Life Sciences
Trusted oncology evidence built for life sciences
In a fast-changing global oncology landscape with new regulations, evolving treatments, and shifting standards of care, you need a strategic partner who turns evidence into confident decisions.
Not all evidence is created equal
Flatiron’s real-world evidence (RWE) brings together high-fidelity, real-world data from patients represented across the US, UK, Germany and Japan with deep oncology expertise, and AI-powered intelligence to help you maximise success across the drug development lifecycle.
6M+
patient records
4
largest cancer geographies
2000+
peer-reviewed publications powered by Flatiron data
45+
global regulatory decisions informed
20+
publications validating our real-world endpoints
100%
of the top 20 oncology life sciences companies partner with Flatiron
We partner with life sciences teams across the drug development lifecycle
-
Natural history and unmet needs
-
Biomarker testing strategy
-
Target Product Profile (TPP) design
-
Trial design and protocol optimization
-
Predictive modeling and digital twins
-
Treatment patterns and survival
-
Cost and resource utilization
-
Natural history and burden of illness
-
Comparative effectiveness
-
Indirect treatment comparisons
-
Clinical decision making analysis
-
Natural history and burden of illness
-
Comparative effectiveness
-
Post-marketing commitments and requirements
-
International transportability
-
HTA submission
-
Risk analysis
-
Fit-for-purpose assessment
-
Response to information request
-
Briefing book composition
-
Health Authority meeting prep and attendance
-
Size market opportunities
-
Launch and market performance
-
HCP segmentation and engagement
-
Prescribing patterns and physician sentiment
Explore our solutions for life sciences organisations
High-quality, global data that reflects how oncology care is actually delivered in the real world
Advanced analytics and expertise built on top of Flatiron RWD to uncover actionable insights across the development lifecycle
Our real-world data is configured to support the evolution of your oncology portfolio
Panoramic data
Flatiron’s largest available patient cohorts are the backbone of a confident real-world evidence strategy.
Multinational data
Power global studies with interoperable data for clinical, commercial, and HTA decisions with unmatched depth in the US, UK, Germany, and Japan.
Multimodal data
Link to imaging results, genomics, pathology, claims, and other in-house or external data sources to unlock greater breadth and depth for real-world analyses.
Custom data
Collaborate with our teams of practicing oncologists, biostatisticians, and epidemiologists to curate novel variables and tailor our real-world data to your specific research needs.
Flatiron’s global network captures how patient care is actually delivered in each market
Our real-world data can help you dive deep into local patient populations, care patterns, and outcomes, but also spot meaningful differences across regions.
Deep oncology expertise
Oncologists, research scientists, data engineers, health equity analysts, regulatory experts: An integrated team of in-house specialists stands ready to jump in to meet your needs, whether you’re shaping your company’s portfolio strategy or defending post-market decisions. From one end of the drug development lifecycle to the other, think of us as an extension of your own team.
